Clinical

Jeff Stark, MD, vice president and head of immunology, UCB, discusses findings on improved pain management in patients with moderate to severe hidradenitis suppurativa (HS).

Despite potential benefits, the therapy remains in limited use for myeloproliferative neoplasms (MPNs).

The report offers new insights into the limits of the BCL2 inhibitor among patients who have myelodysplastic syndromes.

Dupilumab significantly reduced the risk of exacerbations compared with placebo in children with moderate to severe asthma, regardless of exacerbation history.

Vivian Tambe Ebot-Tar, PharmD, MBA, leads a discussion on value-based care models based on real-world evidence for the treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Elias Jabbour, MD, discusses findings from the PhALLCON trial relevant to treatment decisions for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

A study found that cetuximab along or with chemotherapy was an effective option in patients with metastatic colorectal cancer (CRC).

COVID-19 vaccination was associated with reduced risks of acute and post–acute COVID-19 heart failure, venous thromboembolism, and arterial thrombosis/thromboembolism.

Medical experts emphasize the importance of partnering with community leaders to address social determinants of health that act as barriers to care.

The panel discusses the availability of data on cardiovascular outcomes related to gender and minority disparities, including data collection, reporting standards, and minority participation in clinical trials.

A better understanding of biomarkers in ocular graft-vs-host disease (oGVHD) can help drive a more comprehensive understanding of the disease and improve patient outcomes, say researchers.

Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University of Medicine and Science, provided current clinical evidence supporting the use of oral Janus kinase (JAK) inhibitors to treat patients with atopic dermatitis (AD).

This study suggests that dose-escalation or low-dose regimens for roflumilast treatment in patients with chronic obstructive pulmonary disease (COPD) may improve adherence.

The Princess of Wales is likely referencing adjuvant chemotherapy, but there is a growing field of immunoprevention, which seeks to target precancerous lesions or block heritable cancers.

Investigators examined the downstream effect of single-gene testing for guideline-recommended biomarkers on comprehensive genomic profiling in non–small cell lung cancer (NSCLC).

However, researchers saw higher risks of respiratory failure, longer stays in the intensive care unit, increased hospitalizations, and elevated mortality rates in patients with heart failure with reduced ejection fraction (HFrEF) taking the antihypotensive medication.

Risks like tumor lysis syndrome in the setting of chronic lymphocytic leukemia (CLL) require vigilant planning and coordination, authors say.

Interferons have been a major treatment for myeloproliferative neoplasms (MPNs) for decades, but emerging therapies are expanding the treatment armamentarium, explained Raajit Rampal, MD, PhD, of Memorial Sloan Kettering Cancer Center.

The White House has called out the Republican Study Committee’s budget proposal for backing legislation that would put restrictions on abortion access; nearly 108,000 Americans died of drug overdoses in 2022; surgeons in Boston have transplanted a kidney from a genetically engineered pig into an ailing 62-year-old man.

CMS is highly likely to negotiate the price of the obesity medication semaglutide in the coming years; many health care providers are trying to determine whether their cyberattack insurance will help cover their losses after the Change Healthcare hack; the US life expectancy increased for the first time in 2 years.

Increased perceived economic burden (PEB) was associated with an increased risk of mortality and poorer health status among patients with acute decompensated heart failure (HF).

These findings, together with real-world data, could help inform risk classification of myasthenic crisis beyond known risk factors, such as infection.

Reducing or quitting smoking significantly lowered the risk of lung cancer in patients with chronic obstructive pulmonary disease (COPD) who smoked less than 30 pack-years in a recent study.

Patients with colorectal cancer (CRC) and spousal caregivers were found to benefit from a couple-based posttraumatic growth intervention visits in a randomized controlled study.

There is no cure for chronic lymphocytic leukemia (CLL), but new therapeutic options could extend survival, even in cases where the latest treatments have faltered.

A global AIDS program that was in limbo for months got temporary relief after congressional negotiators agreed to a 1-year renewal in the next government funding package; the outcome of the November presidential election could determine the state of fetal tissue research in the US; federal officials and industry executives failed to make improvements that stop hacking attacks.

Once-daily aprocitentan (Tryvio) is the first and only FDA-approved endothelin receptor antagonist for treating high blood pressure that remains uncontrolled despite other antihypertensive treatments.

These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).

Laura Ferris, MD, PhD, professor of dermatology, University of Pittsburgh, reports promising response rates and a good safety profile with JNJ-2113 in patients with moderate to severe plaque psoriasis.

The Duchenne muscular dystrophy (DMD) treatment vamorolone received FDA approval in October 2023 and is a less toxic alternative to conventional corticosteroids.